Learn → Glossary → clinical condition

Nonalcoholic Steatohepatitis

Progressive form of NAFLD with hepatocellular injury, inflammation, and risk of fibrosis and cirrhosis.

Also: NASH

Distinguished from simple steatosis by ballooning hepatocytes and lobular inflammation on biopsy. Affects ~3 to 5% of the U.S. adult population. Sustained 10% weight loss and Mediterranean diet pattern reduce inflammation and fibrosis. Emerging pharmacotherapies (vitamin E, pioglitazone, GLP-1 agonists) target specific patient subsets.

How one textbook covers it

  • Krause and Mahan's Food and the Nutrition Care Process, 16th ed. — Chapter 29

    Distinguished from simple steatosis by ballooning hepatocytes and lobular inflammation on biopsy. Affects ~3 to 5% of the U.S. adult population. Sustained 10% weight loss and Mediterranean diet pattern reduce inflammation and fibrosis. Emerging pharmacotherapies (vitamin E, pioglitazone, GLP-1 agonists) target specific patient subsets.

Related terms

Cirrhosis, Insulin Resistance, NAFLD